



Longboard Pharmaceuticals to Present at Upcoming Investor Conferences

August 3, 2023

LA JOLLA, Calif.--(BUSINESS WIRE)--Aug. 3, 2023-- [Longboard Pharmaceuticals, Inc.](#) (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced members of its leadership team will present at the BTIG Virtual Biotechnology Conference and the Wedbush Annual PacGrow Healthcare Conference in New York City.

Presentation Details:

The conference presentations are intended for BTIG and Wedbush clients only.

Event Title: BTIG Virtual Biotechnology Conference

Presentation Time: Monday, August 7, 2023, at 1:30PM ET

Additional Information: *This conference is being hosted by BTIG, a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. To join the conference, email info@btig.com.*

Event Title: Wedbush 14th Annual PacGrow Healthcare Conference

Panel Title: *David vs. Goliath - How Can Orphan Epilepsy Development Accelerate and Broaden its Reach?*

Panel Presentation Time: Wednesday, August 9, 2023, at 9:30AM ET

Additional Information: *Please contact your Wedbush representative for conference details.*

ABOUT LONGBOARD PHARMACEUTICALS

[Longboard Pharmaceuticals, Inc.](#) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting [product candidates](#) designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard's small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of multiple neurological diseases.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard's participation in upcoming investor conferences and Longboard's clinical and preclinical programs and product candidates, ability to develop product candidates and deliver medicines, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard's expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard's forward-looking statements are disclosed in Longboard's filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard's judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230803274904/en/): <https://www.businesswire.com/news/home/20230803274904/en/>

Megan E. Knight
Head of Investor Relations
IR@longboardpharma.com
858.789.9283

Source: Longboard Pharmaceuticals, Inc.